The control of HIV after antiretroviral medication pause (CHAMP) study: Posttreatment controllers identified from 14 clinical studies

Golnaz Namazi, Jesse M. Fajnzylber, Evgenia Aga, Ronald J. Bosch, Edward P. Acosta, Radwa Sharaf, Wendy Hartogensis, Jeffrey M. Jacobson, Elizabeth Connick, Paul Volberding, Daniel Skiest, David Margolis, Michael C. Sneller, Susan J. Little, Sara Gianella, Davey M. Smith, Daniel R. Kuritzkes, Roy M. Gulick, John W. Mellors, Vikram MehrajRajesh T. Gandhi, Ronald Mitsuyasu, Robert T. Schooley, Keith Henry, Pablo Tebas, Steven G. Deeks, Tae Wook Chun, Ann C. Collier, Jean Pierre Routy, Frederick M. Hecht, Bruce D. Walker, Jonathan Z. Li

Research output: Contribution to journalArticlepeer-review

117 Scopus citations


Background. HIV posttreatment controllers are rare individuals who start antiretroviral therapy (ART), but maintain HIV suppression after treatment interruption. The frequency of posttreatment control and posttreatment interruption viral dynamics have not been well characterized. Methods. Posttreatment controllers were identified from 14 studies and defined as individuals who underwent treatment interruption with viral loads ≤400 copies/mL at two-thirds or more of time points for ≥24 weeks. Viral load and CD4+ cell dynamics were compared between posttreatment controllers and noncontrollers. Results. Of the 67 posttreatment controllers identified, 38 initiated ART during early HIV infection. Posttreatment controllers were more frequently identified in those treated during early versus chronic infection (13% vs 4%, P < .001). In posttreatment controllers with weekly viral load monitoring, 45% had a peak posttreatment interruption viral load of ≥1000 copies/mL and 33% had a peak viral load ≥10 000 copies/mL. Of posttreatment controllers, 55% maintained HIV control for 2 years, with approximately 20% maintaining control for ≥5 years. Conclusions. Posttreatment control was more commonly identified amongst early treated individuals, frequently characterized by early transient viral rebound and heterogeneous durability of HIV remission. These results may provide mechanistic insights and have implications for the design of trials aimed at achieving HIV remission.

Original languageEnglish (US)
Pages (from-to)1954-1963
Number of pages10
JournalJournal of Infectious Diseases
Issue number12
StatePublished - Nov 5 2018


  • HIV
  • HIV rebound
  • Posttreatment controller
  • Treatment interruption
  • Viral decay

ASJC Scopus subject areas

  • General Medicine


Dive into the research topics of 'The control of HIV after antiretroviral medication pause (CHAMP) study: Posttreatment controllers identified from 14 clinical studies'. Together they form a unique fingerprint.

Cite this